Vitae Pharmaceuticals’ executive management team and accomplished drug discovery scientists possess substantial experience across the full spectrum of drug discovery, development and commercialization.
The company’s Chief Executive Officer, Jeffrey S. Hatfield, previously held a number of executive and commercial positions at Bristol-Myers Squibb Company, or BMS, where he successfully launched products in several therapeutic areas. Richard Gregg, M.D., Vitae Pharmaceuticals’ Chief Scientific Officer, was previously head of Clinical Discovery of BMS, where he was involved in the development of all of BMS’ compounds from preclinical candidate selection through to human proof-of-concept. The company’s Chief Financial Officer, Richard Morris, previously worked at ViroPharma Incorporated and KPMG LLP in their Healthcare Assurance practice. Arthur Fratamico, R.Ph., Vitae Pharmaceuticals’ Chief Business Officer, previously served as chief business officer of Flexion Therapeutics, Inc., and led business development efforts at several private and public biotechnology companies including Trevena, Inc., Gemin X Pharmaceuticals, and MGI Pharma, Inc. Carole Sable, M.D., the company’s Chief Medical Officer, was previously Chief Medical Officer of REVOLUTION Medicines. Prior to Revolution Medicines, she served in similar roles in several pharmaceutical companies including SCYNEXIS Inc. as well as senior medical positions at Merck & Co.
In addition, Vitae Pharmaceuticals’ business and R&D teams are supported by a group of investors and advisors with significant expertise in developing pharmaceutical enterprises and enhancing their impact, capabilities and results.
Jeff Hatfield joined Vitae Pharmaceuticals as President, Chief Executive Officer and a member of the Board of Directors in March 2004. Since becoming CEO, he has successfully transitioned Vitae from a novel technology start-up to a thriving product-focused discovery and development engine with a robust pipeline that includes multiple programs advancing in human clinical trials. Mr. Hatfield has focused the company on high value therapeutic areas with significant global unmet medical need, including diabetes, Alzheimer’s disease, autoimmune disorders, acute coronary syndrome, atopic dermatitis and immuno-oncology. Notably, since joining the company Mr. Hatfield has grown shareholder value in a uniquely capital efficient way – Vitae’s last venture round dates back to 2004, his first year with the company.
Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked at Bristol-Myers Squibb in a variety of executive positions, including: Senior Vice President of BMS’s Virology and Immunology Divisions, where he was responsible for all aspects of the $1 billion business; President and General Manager, Canada; and, Vice President, U.S. Managed Health Care. While at BMS, Mr. Hatfield was directly associated with several product successes, including Pravachol®, Plavix®, Avapro®, Abilify®, Reyataz® and Atripla®.
Mr. Hatfield holds an M.B.A. from The Wharton School, University of Pennsylvania and a bachelor’s degree in Pharmacy from Purdue University, where he is a Distinguished Alumni. He is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Executive Committee of the Emerging Company Section. He is a board member of Ambit Biosciences, and is also a member of the Advisory Committees for Purdue University’s College of Pharmacy, Drexel University’s LeBow College of Business and the Chapman-KGI School of BioPharmacy.
Dr. Gregg spent 19 years leading various groups at Bristol-Myers Squibb Research and Development before deciding to join Vitae Pharmaceuticals. Most recently, he was Vice President of Clinical Discovery, responsible for Early Clinical Development, Clinical Pharmacology, Translational Medicine and Biomarker Technologies. Dr. Gregg developed and led the Bristol’s efforts in the application of cutting edge science and analytical technologies to the clinical investigation of new drugs. He also served as Vice President of Metabolic and Cardiovascular Drug Discovery, focusing on the discovery of new drugs for diabetes, dyslipidemia, and atherosclerotic vascular disease. Before coming to Bristol, Dr. Gregg spent 10 years at the National Heart, Lung and Blood Institute, where he studied disorders of lipid and lipoprotein metabolism. He has more than 120 publications in leading medical and research journals, and has presented his research findings at national and international meetings. Dr. Gregg earned his B.S. and M.S. from Iowa State University and his M.D. from Stanford University School of Medicine. He did his internship and residency in Internal Medicine at Strong Memorial Hospital in Rochester, New York, and completed his fellowship in Endocrinology and Metabolism at the National Institutes of Health.
Richard Morris, CPA has served as our Chief Financial Officer since May 2014. Prior to joining us, Mr. Morris worked at ViroPharma Incorporated, which he joined in 2001, in a variety of positions, including Vice President, Financial Planning and Strategic Analysis from 2012 to 2014, Vice President, Chief Accounting Officer from 2011 to 2014, Controller and Chief Accounting Officer from 2008 April 2011 and Controller from 2005 through 2008. Prior to joining ViroPharma, Mr. Morris worked for KPMG LLP in their Healthcare Assurance practice. Mr. Morris received a bachelor’s degree in Accounting from Saint Joseph’s University and has been a CPA since 1999.
Arthur Fratamico, R.Ph. has served as our Chief Business Officer since May 2014. Prior to joining us, Mr. Fratamico served as chief business officer of Flexion Therapeutics, Inc. from June 2012 through 2014. Prior to Flexion, Mr. Fratamico led the business development efforts, including overseeing numerous licensing transactions and acquisitions, at private biotechnology companies including Trevena, Inc. from 2011 to 2012, Gemin X Pharmaceuticals, Inc. from 2008 to 2011 and MGI Pharma, Inc. from 1999 to 2008. Mr. Fratamico earned a bachelor’s degree in pharmacy from the Philadelphia College of Pharmacy and an M.B.A. from Drexel University.
Dr. Sable brings to Vitae more than 20 years of diverse clinical development and executive management experience, having been involved in all phases of clinical research, including the filing of several New Drug Applications with the U.S. Food and Drug Administration, as well as multiple Worldwide Marketing Applications. She most recently served as Chief Medical Officer of REVOLUTION Medicines, Inc. Prior to REVOLUTION Medicines, Dr. Sable served as Chief Medical Officer at SCYNEXIS, Inc. In this role, she was responsible for all clinical development, clinical pharmacology and regulatory activities. Earlier in her career, Dr. Sable has held several senior positions at Merck & Co., Inc., where she oversaw preparation of the New Drug Application for BELSORMA®, leading to its approval in 2014. Dr. Sable also served as Chief Medical Officer of Novexel SA, where she led worldwide clinical development activities until the company’s acquisition by AstraZeneca in 2010. Additionally, she has authored nearly 60 scientific reviews and articles. Dr. Sable was an Assistant Professor of Medicine and Infectious Diseases at the University of Virginia in Charlottesville. She received a BS from the University of Scranton and an MD from Jefferson Medical College in 1983. She completed an internal medicine residency and infectious disease fellowship at the University of Virginia.
Dr. Claremon has over 30 years of experience in Medicinal Chemistry, gained at Merck & Co., where he was Senior Director, Medicinal Chemistry, and as head of chemistry at Vitae Pharmaceuticals. While at Merck, his research group successfully identified several development candidates including an anti-arrhythmic, an oral fibrinogen receptor antagonist, and an NR2B selective NMDA receptor antagonist. He has co-authored more than 70 publications and is listed as an inventor on 110 patents. He received a Bachelor’s degree in Chemistry from Case Western Reserve University and a Ph.D. from the University of Pennsylvania in Organic Chemistry, where he studied with Professor K.C. Nicolaou.
Dr. McGeehan was Executive Director of Lead Discovery at the DuPont Pharmaceuticals Company in Wilmington, Delaware before coming to Vitae Pharmaceuticals in 2002. He was also at Glaxo Inc. (RTP), for seven years, last serving as head of the Biochemistry Department. At Rhone-Poulenc Rorer, he was Director of Inflammation and established the Department of Lead Generation. Dr. McGeehan’s research interests have included the pharmacology of proteolytic enzymes and receptors, new assay methods and exploration of problems at the biology/chemistry interface. Dr. McGeehan received his Ph.D. in Organic Chemistry from Stanford University and served as an NSF post-doctoral fellow at the ETH-Zurich.